Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia

Osteoporosis International

Volumn 21, Issue 4, 2010, Pages 655-666

  Saito, M ^a   Marumo, K ^a   Soshi, S ^a   Kida, Y ^a   Ushiku, C ^a   Shinohara, A ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Collagen cross links; Homocysteine; Osteoporosis; Pentosidine; Raloxifene

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN; DEOXYPYRIDINOLINE; HOMOCYSTEINE; HYDROXYPROLINE; METHIONINE; PENTOSIDINE; PROTEIN LYSINE 6 OXIDASE; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; CONTROLLED STUDY; CROSS LINKING; DISEASE MODEL; ENZYME ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERHOMOCYSTEINEMIA; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RABBIT; STRESS STRAIN RELATIONSHIP; TREATMENT DURATION; WEIGHT BEARING; YOUNG MODULUS;

ANIMALS; ARGININE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERHOMOCYSTEINEMIA; LYSINE; METHIONINE; OSTEOPOROSIS; RABBITS; RALOXIFENE; STRESS, MECHANICAL;

EID: 77950921735     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0980-4     Document Type: Article

References (60)

1. SeemanE,DelmasPD(2006)Bonequality- thematerialandstructuralbasisofbonestrengthandfragility.NEnglJMed354: 2250-2261(Pubitemid43788139)
2. Burr DB (2002) Bone material properties and mineral matrix contributions to fracture risk or age in women and men. J Musculoskelet Neuronal Interact 2:201-204
3. Paschalis EP, Shane E, Lyritis G et al (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000-2004
4. Vashishth D (2007) The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 5:62-66
5. Wang X, Shen X, Li X et al (2002) Age-related changes in the collagen network and toughness of bone. Bone 31:1-7 (Pubitemid 34754417)
6. Saito M, Fujii K, Mori Y et al (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17:1514-1523 (Pubitemid 44387486)
7. Oxlund H, Mosekilde L, Ortoft G (1996) Reduced concentration of collagen reducible crosslinks in human trabecular bone with respect to age and osteoporosis. Bone 19:479-484 (Pubitemid 126745126)
8. Banse X, Sims TJ, Bailey AJ (2002) Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 17:1621-1628
9. Paschalis EP, Recker R, Dicarlo E et al (2003) Distribution of collagen cross-links in normal human trabecular bone. J Bone Miner Res 18:1942-1946 (Pubitemid 37377442)
10. Saito M, Soshi S, Fujii K (2003) Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. J Bone Miner Res 18:1695-1705 (Pubitemid 37022929)
11. Uzawa K, Grzesik WJ, Nishiura T et al (1999) Differential expression of human lysyl hydroxylase genes, lysyl hydroxylation, and cross-linking of type I collagen during osteoblastic differentiation in vitro. J Bone Miner Res 14:1272-1280 (Pubitemid 29368289)
12. McLean RR, Jacques PF, Selhub J et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042-2049 (Pubitemid 38596555)
13. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 35:2033-2041
14. McKusick VA (1966) Heritable disorders of connective tissue, 3rd edn. C.V. Mosby, St. Louis, p 155
15. Lubec B, Fang-Kircher S, Lubec T et al (1996) Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 13:159-162
16. Saito M, Sohsi S, Tanaka T et al (2004) Intensity-related differences in collagen post-translational modification in MC3T3-E1 osteoblasts after exposure to low and high intensity pulsed ultrasound. Bone 35:644-655 (Pubitemid 39141865)
17. McCarthy AD, Etcheverry SB, Bruzzone L et al (2001) Nonenzymatic glycation of a type I collagen matrix: effect on osteoblastic development and oxidative stress. BMC Cell Biol 2:16 (Pubitemid 38597710)
18. Garnero P, Borel O, Gineyts E et al (2006) Extracellular posttranslational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38:300-309 (Pubitemid 43255423)
19. Blouin S, Thaler HW, Korninger C et al (2009) Bone matrix quality and plasma homocysteine levels. Bone 44:959-964
20. Saito M, Fujii K, Marumo K (2006) Degree of mineralizationrelated collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79:160-168 (Pubitemid 44440444)
21. Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330-337 (Pubitemid 38116748)
22. Recker RR, Kendler D, Recknor CP et al (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in post-menopausal women with low bone mass. Bone 40:843-851 (Pubitemid 46386535)
23. Allen MR, Gynets E, Leeming DJ et al (2008) Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 19:329-337
24. Walsh BW, Paul S, Wild RA et al (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85:214-218 (Pubitemid 32268816)
25. De Leo V, la Marca A, Morgante G et al (2001) Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 84:350-353 (Pubitemid 32206982)
26. Toborek M, Kopieczna-Grzebieniak E, Drozdz M et al (1995) Increases lipid peroxidation as a mechanism of methionineinduced atherosclerosis in rabbit. Atherosclerosis 115:217-224
27. Bjarnason NH, Haarbo J, Byrjalsen I et al (2000) Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol 52:225-233 (Pubitemid 30108270)
28. Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43-52 (Pubitemid 17167357)
29. Saito M, Marumo K, Fujii K et al (1997) Single column high-performance liquid chromatographic-fluorescence detection of immature, mature and senescent cross-links of collagen. Anal Biochem 253:26-32 (Pubitemid 27490600)
30. Nonaka K, Fukuda S, Aoki K et al (2006) Regional distinctions in cortical bone mineral density measured by pQCT can predict alterations in material properties at the tibial diaphysis of the Cynomolgus monkey. Bone 38:265-272 (Pubitemid 43165792)
31. Manabe T, Mori S, Mashiba T et al (2007) Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40:1475-1482 (Pubitemid 46756411)
32. Turner CH, Akhter MP, Heaney RP (1992) The effects of fluoridated water on bone strength. J Orthop Res 10:581-587
33. Castaneda S, Calvo E, Largo R et al (2008) Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab 26:53-59 (Pubitemid 350308010)
34. Shukla N, Koupparis A, Jones RA et al (2006) Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium- dependent relaxation and superoxide formation in the aorta of the rabbit. Eur J Pharmacol 531:201-208 (Pubitemid 43202236)
35. Narin F, Narin N, Akcakus M et al (2002) The effect of folic acid, vitamin B6 and vitamin B12 on the homocysteine levels in rabbits fed by methionine-enriched diets. Tohoku J Exp Med 198:99-105 (Pubitemid 36097847)
36. Saito M, Mori S, Mashiba T et al (2008) Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19:1343-1354
37. BellinoFL(2000)Nonprimateanimalmodelsofmenopause:workshopreport. Menopause7:14-24(Pubitemid30043891)
38. Silva MJ, Brodt MD, Wopenka B et al (2006) Decreased collagen organization and content are associated with reduced strength of demineralized and intact bone in the SAMP6 mouse. J Bone Miner Res 21:78-88 (Pubitemid 43023229)
39. Saito M, Fujii K, Soshi S et al (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986-995 (Pubitemid 43864852)
40. Shiraki M, Urano T, Kuroda T et al (2008) The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fracture. J Bone Miner Metab 26:595-602
41. Turecek C, Fratzl-Zelman N, Rumpler M (2008) Collagen crosslinking influences osteoblastic differentiation. Calcif Tissue Int 82:392-400
42. OzasaH,TominagaT,NishimuraTetal(1981) Lysyloxidaseactivityinthemouseuterinecervixisphysiologicallyregulatedbyestrogen. Endocrinology109:618-621(Pubitemid11040222)
43. Hak AE, Polderman KH, Westendorp IC et al (2000) Increased plasma homocysteine after menopause. Atherosclerosis 149:163-168
44. Russo GT, Di Benedetto A, Alessi E et al (2008) Menopause modulates homocysteine levels in diabetic and non-diabetic women. J Endocrinol Invest 31:546-551
45. Herrmann M, Tami A, Wildemann B et al (2008) Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 44:467-475
46. Herrmann M, Peter Schmidt J, Umanskaya N et al (2007) The role of hyperhomocysteinemia as well as folate, vitamin B(6) and B (12) deficiencies in osteoporosis: a systematic review. Clin Chem Lab Med 45:1621-1632 (Pubitemid 350232987)
47. Raposo B, Rodriguez C, Martinez-Gonzalez J et al (2004) High levels of homocysteine inhibit lysyl oxidase (LOX) and down regulate LOX expression in vascular endothelial cells. Atherosclerosis 177:1-8 (Pubitemid 39361132)
48. Kang HA, Trelstad RL (1973) A collagen defect in homocystinuria. J Clin Invest 52:2571-2578
49. Reiser KM (1991) Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med 196:17-29
50. EberhardtRT,ForgioneMA,CapAetal(2000) Endothelialdysfunctioninamurinemodelofmildhyperhomocyst(e)inemia.JClinInvest106: 483-491(Pubitemid30666381)
51. Castelo-Branco C, Sanjuan A, Casals E et al (2004) Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits. J Obstet Gynaecol 24:47-51 (Pubitemid 38130330)
52. Khastgir G, Studd J, Holland N et al (2001) Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 12:465-470 (Pubitemid 32607089)
53. Paschalis EP, Boskey AL, Kassem M et al (2003) Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 18:955-959 (Pubitemid 37294931)
54. Faibish D, Ott SM, Bosky AL (2006) Mineral changes in osteoporosis - a review. Clin Orthop Relat Res 443:28-38
55. Yang NN, Bryant HU, Hardikar S et al (1996) Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifenemediated bone maintenance. Endocrinology 137:2075-2084 (Pubitemid 26133978)
56. Feres-Filho EJ, Choi YJ, Han X et al (1995) Pre- and posttranslational regulation of lysyl oxidase by transforming growth factor-beta 1 in osteoblastic MC3T3-E1 cells. J Biol Chem 270:30797-30803 (Pubitemid 26005149)
57. Shibata Y, Abiko Y, Moriya Y et al (1993) Effects of transforming growth factor-beta on collagen gene expression and collagen synthesis level in mineralizing cultures of osteoblast-like cell line, MC3T3-E1. Int J Biochem 25:239-245 (Pubitemid 23045836)
58. Helvering LM, Liu R, Kulkarni N et al (2005) Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. Mol Pharmacol 68:1225-1238 (Pubitemid 41539980)
59. Mann V, Huber C, Kogianni G et al (2007) The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 40:674-684 (Pubitemid 46201947)
60. Brady JD, Robins SP (2001) Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. J Biol Chem 276:18812-18818 (Pubitemid 37411198)